Recently, the U.S. FDA has approved Bimzelx (Bimekizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Bimekizumab is the first approved IL-17A/F inhibitor for the treatment of moderate to severe plaque psoriasis. Bimzelx is a fully humanized monoclonal antibody that can strongly and specifically neutralize IL-17A and IL-17F. IL-17A plays a crucial role in the pathogenesis of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Psoriasis is a chronic autoimmune skin disorder characterized by the rapid and excessive growth of skin cells. This leads to the formation of thick, red, scaly patches, known as plaques, on the skin's surface. Psoriasis is not contagious, and its exact cause is not fully understood, but it is believed to involve a combination of genetic and environmental factors. October 29^th of every year is "World Psoriasis Day", a special day dedicated to all psoriasis patients worldwide. Its establishment is aimed at urging people across the globe to understand psoriasis, clarify common misconceptions about the condition, and enhance awareness among psoriasis patients.The theme of World Psoriasis Day 2023 is "Access for All".

Traditional treatments for psoriasis primarily involve the use of retinoids, immunosuppressants, and phototherapy. However, these treatments often yield suboptimal results and are associated with severe adverse effects. With advancing scientific research into the causes of psoriasis, key inflammatory factors such as TNFα, IL-17, and IL-12/23 have been identified as crucial contributors to the development of psoriasis. Blocking these pathways can prevent the onset of psoriasis. In response to these discoveries, scientists have developed a variety of biologic agents for psoriasis treatment. The essence of biologic treatments lies in their "precision targeting." Traditional medications often employ a "broad-spectrum attack" approach, which can result in collateral damage, delayed efficacy, a high incidence of adverse effects, and difficulties in treatment adherence. In contrast, biologic agents are designed based on a deep understanding of the disease's mechanisms, allowing for highly specific targeting with clear molecular targets. This "precision strike" approach offers direct benefits, including high efficiency, long-lasting effects, and a relatively lower occurrence of adverse reactions.

Globally, approximately 125 million people are affected by psoriasis, there is a substantial market demand for specific and effective medications tailored for psoriasis.

Regarding psoriasis, GemPharmatech has independently developed two disease models: the IMQ-induced psoriasis mouse model and the B6-K14-hIL17A spontaneous psoriasis mouse model. These models serve as valuable tools for studying the disease mechanisms and evaluating potential therapeutic approaches.

Humanized mouse resources related to psoriasis